NCT05138458 - A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

November 30, 2024

Study Completion Date

October 31, 2025

Conditions

Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousMycosis FungoidesAdoptive Cellular ImmunotherapyCell Therapy

Interventions

BIOLOGICAL

MT-101

CD5 ATAK cells

OTHER

MT-101 + Conditioning (Lymphodepleting) Chemotherapy

IV administration of fludarabine and cyclophosphamide

Trial Locations (6)

Thomas Jefferson University, Philadelphia

University of Virginia Comprehensive Cancer Center, Charlottesville

University of Texas MD Anderson Cancer Center, Houston

Colorado Blood Cancer Institute, Denver

City of Hope Comprehensive Cancer Center, Duarte

Dana-Farber/Mass General Brigham Cancer Care, Boston